[1] 赵冬,杨丽霞,赵绮旎.急性心梗流行病学特征及危险因素的调查分析[J].实用预防医学,2022,29(9):1124-1126.
[2] Wu X, Reboll MR, Korf-Klingebiel M, et al.Angiogenesis after acute myocardial infarction[J]. Cardiovasc Res, 2021, 117(5): 1257-1273.
[3] Thiele H, Zahn R.Acute myocardial infarction-actual issues[J].Herz, 2020, 45(6): 507-508.
[4] 高敏,李宏宾,刘启龙,等.TM、TAT、PIC、t-PAIC对冠心病的诊断价值及支持向量机鉴别诊断模型的建立[J].中西医结合心脑血管病杂志,2023,21(1):133-138.
[5] 曾镇桦,高海闽,黄绍生,等.脓毒症患者TAT、TM、PIC和t-PAIC水平与病情程度的关系[J].疑难病杂志,2021,20(12):1240-1243.
[6] 朱迎伟,褚旭,邱家勇,等.血清Apelin-13、可溶性血栓调节蛋白、锁链素对急性肺栓塞患者病情及预后的评估价值[J].临床肺科杂志,2021,26(2):168-173.
[7] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J].中华心血管病杂志,2019,47(10):766-783.
[8] Jones DA, Wright P, Alizadeh MA, et al.The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction[J]. Eur Heart J Cardiovasc Pharmacother, 2021, 7(5): 398-404.
[9] De Luca L, Putini RL, Natale E, et al.One-year clinical outcome of patients with left ventricular thrombus after acute myocardial infarction discharged on triple or dual antithrombotic therapy[J]. J Thromb Thrombolysis, 2022, 53(2): 410-416.
[10] Kumano O, Ieko M, Komiyama Y, et al.Characterization of fibrin/fibrinogen degradation products reagents and their utility in critical care patients with enhanced fibrinolysis[J]. Int J Lab Hematol, 2021, 43(4): 813-820.
[11] 郝立君,贾海英,黄睿.应用凝血标志物预测多发性骨髓瘤患者血栓前状态病例对照研究[J].新疆医科大学学报,2021,44(2):201-204.
[12] 宋小丽. 血清组织型纤溶酶原激活物-抑制剂复合物和膜联蛋白A2及核转录过氧化物酶增殖体激活受体γ与冠心病患者冠状动脉狭窄程度相关性及其对预后的影响[J].中华实用诊断与治疗杂志,2021,35(6):556-560.
[13] Manderstedt E, Halldén C, Lind-Halldén C, et al.Thrombomodulin (THBD) gene variants and thrombotic risk in a population-based cohort study[J]. J Thromb Haemost, 2022, 20(4): 929-935.
[14] 吴玉. 血栓相关指标检测对急性心肌梗死患者发生主要不良心血管事件的预测价值[J].中国当代医药,2023,30(2):163-166,170
[15] 吕永楠,任玮,陈晶晶,等.急性心肌梗死患者血栓标志物水平变化及意义[J].微循环学杂志,2017,27(3):43-46. |
